Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RESprotect GmbH
BioNotebook: Three licenses and a royalty deal; Ligand/Avion, RedHill/RESprotect and more
Summer is for relaxing, but biotechnology companies like Avion Pharmaceuticals and investors like DRI Capital remain focused on licensing key programs or buying new revenue streams.
RESprotect regains pancreatic anticancer and a green light to resume development
SciClone Pharmaceuticals has returned the North American rights to the anticancer drug RP101 to privately owned German oncology firm RESprotect which it obtained in 2007.
Investment gains to advance Acuvax's vaccine ambitions
Acuvax has divested to an unnamed European company its 10% holding in the private German oncology firm RESprotect. The Australian venture retains an interest in RESprotect's lead project, RP101 (BVdU), which is being developed by SciClone Pharmaceuticals.
Deals Shaping the Medical Industry (5/07)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.